These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34927793)

  • 1. Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern.
    Wagner TR; Schnepf D; Beer J; Ruetalo N; Klingel K; Kaiser PD; Junker D; Sauter M; Traenkle B; Frecot DI; Becker M; Schneiderhan-Marra N; Ohnemus A; Schwemmle M; Schindler M; Rothbauer U
    EMBO Rep; 2022 Feb; 23(2):e53865. PubMed ID: 34927793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice.
    Pavan MF; Bok M; Betanzos San Juan R; Malito JP; Marcoppido GA; Franco DR; Militelo DA; Schammas JM; Bari SE; Stone W; López K; Porier DL; Muller JA; Auguste AJ; Yuan L; Wigdorovitz A; Parreño VG; Ibañez LI
    Viruses; 2024 Jan; 16(2):. PubMed ID: 38399961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.
    Casasnovas JM; Margolles Y; Noriega MA; Guzmán M; Arranz R; Melero R; Casanova M; Corbera JA; Jiménez-de-Oya N; Gastaminza P; Garaigorta U; Saiz JC; Martín-Acebes MÁ; Fernández LÁ
    Front Immunol; 2022; 13():863831. PubMed ID: 35547740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2.
    Longsompurana P; Rungrotmongkol T; Plongthongkum N; Wangkanont K; Wolschann P; Poo-Arporn RP
    PLoS One; 2023; 18(10):e0293263. PubMed ID: 37874836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern.
    Wu D; Cong J; Wei J; Hu J; Sun W; Ran W; Liao C; Zheng H; Ye L
    Int J Nanomedicine; 2023; 18():5781-5795. PubMed ID: 37869063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.
    Han Q; Wang S; Wang Z; Zhang C; Wang X; Feng N; Wang T; Zhao Y; Chi H; Yan F; Xia X
    Virol Sin; 2023 Oct; 38(5):787-800. PubMed ID: 37423308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies.
    Wagner TR; Ostertag E; Kaiser PD; Gramlich M; Ruetalo N; Junker D; Haering J; Traenkle B; Becker M; Dulovic A; Schweizer H; Nueske S; Scholz A; Zeck A; Schenke-Layland K; Nelde A; Strengert M; Walz JS; Zocher G; Stehle T; Schindler M; Schneiderhan-Marra N; Rothbauer U
    EMBO Rep; 2021 May; 22(5):e52325. PubMed ID: 33904225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity.
    Chen WH; Hajduczki A; Martinez EJ; Bai H; Matz H; Hill TM; Lewitus E; Chang WC; Dawit L; Peterson CE; Rees PA; Ajayi AB; Golub ES; Swafford I; Dussupt V; David S; Mayer SV; Soman S; Kuklis C; Corbitt C; King J; Choe M; Sankhala RS; Thomas PV; Zemil M; Wieczorek L; Hart T; Duso D; Kummer L; Yan L; Sterling SL; Laing ED; Broder CC; Williams JK; Davidson E; Doranz BJ; Krebs SJ; Polonis VR; Paquin-Proulx D; Rolland M; Reiley WW; Gromowski GD; Modjarrad K; Dooley H; Joyce MG
    Nat Commun; 2023 Feb; 14(1):580. PubMed ID: 36737435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.
    Favorskaya IA; Shcheblyakov DV; Esmagambetov IB; Dolzhikova IV; Alekseeva IA; Korobkova AI; Voronina DV; Ryabova EI; Derkaev AA; Kovyrshina AV; Iliukhina AA; Botikov AG; Voronina OL; Egorova DA; Zubkova OV; Ryzhova NN; Aksenova EI; Kunda MS; Logunov DY; Naroditsky BS; Gintsburg AL
    Front Immunol; 2022; 13():822159. PubMed ID: 35281053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance.
    Walter JD; Scherer M; Hutter CAJ; Garaeva AA; Zimmermann I; Wyss M; Rheinberger J; Ruedin Y; Earp JC; Egloff P; Sorgenfrei M; Hürlimann LM; Gonda I; Meier G; Remm S; Thavarasah S; van Geest G; Bruggmann R; Zimmer G; Slotboom DJ; Paulino C; Plattet P; Seeger MA
    EMBO Rep; 2022 Apr; 23(4):e54199. PubMed ID: 35253970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.
    Ma H; Zhang X; Zheng P; Dube PH; Zeng W; Chen S; Cheng Q; Yang Y; Wu Y; Zhou J; Hu X; Xiang Y; Zhang H; Chiu S; Jin T
    Cell Res; 2022 Sep; 32(9):831-842. PubMed ID: 35906408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of nanobodies neutralizing SARS-CoV-2 variants.
    Shi Z; Li X; Wang L; Sun Z; Zhang H; Chen X; Cui Q; Qiao H; Lan Z; Zhang X; Li X; Li L; Xu J; Gong R; Fan C; Geng Y
    Structure; 2022 May; 30(5):707-720.e5. PubMed ID: 35276082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope.
    Liu Z; Xu W; Chen Z; Fu W; Zhan W; Gao Y; Zhou J; Zhou Y; Wu J; Wang Q; Zhang X; Hao A; Wu W; Zhang Q; Li Y; Fan K; Chen R; Jiang Q; Mayer CT; Schoofs T; Xie Y; Jiang S; Wen Y; Yuan Z; Wang K; Lu L; Sun L; Wang Q
    Protein Cell; 2022 Sep; 13(9):655-675. PubMed ID: 34554412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift.
    Laroche A; Orsini Delgado ML; Chalopin B; Cuniasse P; Dubois S; Sierocki R; Gallais F; Debroas S; Bellanger L; Simon S; Maillère B; Nozach H
    MAbs; 2022; 14(1):2076775. PubMed ID: 35593235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants.
    Hong J; Kwon HJ; Cachau R; Chen CZ; Butay KJ; Duan Z; Li D; Ren H; Liang T; Zhu J; Dandey VP; Martin NP; Esposito D; Ortega-Rodriguez U; Xu M; Borgnia MJ; Xie H; Ho M
    Proc Natl Acad Sci U S A; 2022 May; 119(18):e2201433119. PubMed ID: 35476528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization.
    Yang J; Lin S; Chen Z; Yang F; Guo L; Wang L; Duan Y; Zhang X; Dai Y; Yin K; Yu C; Yuan X; Sun H; He B; Cao Y; Ye H; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
    PLoS Pathog; 2023 Nov; 19(11):e1011804. PubMed ID: 38033141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.